Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.

Tytuł:
Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
Autorzy:
Zemrak W; Department of Pharmacy, Maine Medical Center, Portland, ME, 04105, USA. .
Manuel F; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Smith KE; Department of Pharmacy, Maine Medical Center, Portland, ME, 04105, USA.
Rolfe S; Department of Pharmacy, Maine Medical Center, Portland, ME, 04105, USA.
Hayes T; Department of Pathology, Maine Medical Center, Portland, ME, USA.
Trowbridge RL; Department of Medicine, Maine Medical Center, Portland, ME, USA.
Carlone B; Department of Pharmacy, Maine Medical Center, Portland, ME, 04105, USA.
Seder D; Department of Critical Care Services, Maine Medical Center, Portland, ME, USA.
Źródło:
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2019 Feb; Vol. 47 (2), pp. 263-271.
Typ publikacji:
Comparative Study; Journal Article; Observational Study
Język:
English
Imprint Name(s):
Original Publication: [Dordrecht ; Norwell, MA] : Kluwer Academic Publishers, c1994-
MeSH Terms:
Anticoagulants*/administration & dosage
Anticoagulants*/adverse effects
Blood Coagulation Factors/*administration & dosage
Hemorrhage/*drug therapy
Hemostasis/*drug effects
Heparin Antagonists/*administration & dosage
Warfarin/*antagonists & inhibitors
Aged ; Aged, 80 and over ; Blood Coagulation Factors/adverse effects ; Body Weight ; Drug Dosage Calculations ; Drug Monitoring/methods ; Female ; Hemorrhage/chemically induced ; Hemorrhage/diagnosis ; Heparin Antagonists/adverse effects ; Humans ; International Normalized Ratio ; Male ; Models, Biological ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Treatment Outcome ; Warfarin/administration & dosage ; Warfarin/adverse effects
References:
Thromb Res. 2005;115(6):455-9. (PMID: 15792675)
Thromb Res. 2006;118(3):313-20. (PMID: 16182346)
Hematology. 2007 Oct;12(5):439-40. (PMID: 17852462)
Transfus Med. 2011 Apr;21(2):116-23. (PMID: 21073580)
Chest. 2012 Feb;141(2 Suppl):e152S-e184S. (PMID: 22315259)
Haematologica. 2012 Oct;97(10):1501-6. (PMID: 22491734)
Transfusion. 2013 Jul;53(7):1451-8; quiz 1450. (PMID: 23067393)
Circulation. 2013 Sep 10;128(11):1234-43. (PMID: 23935011)
Thromb Haemost. 2014 Feb;111(2):233-9. (PMID: 24154891)
JAMA. 2015 Feb 24;313(8):824-36. (PMID: 25710659)
Lancet. 2015 May 23;385(9982):2077-87. (PMID: 25728933)
J Thromb Haemost. 2016 Jan;14(1):211-4. (PMID: 26391431)
Neurocrit Care. 2016 Feb;24(1):6-46. (PMID: 26714677)
Am J Emerg Med. 2016 Aug;34(8):1736.e1-3. (PMID: 26806175)
Neurocrit Care. 2017 Feb;26(1):64-69. (PMID: 27052728)
J Neuroimaging. 2017 Jan;27(1):144-148. (PMID: 27300754)
Lancet Neurol. 2016 May;15(6):566-73. (PMID: 27302126)
Neurocrit Care. 2017 Dec;27(3):334-340. (PMID: 28660341)
J Thromb Thrombolysis. 2018 Feb;45(2):300-305. (PMID: 29164374)
J Am Coll Cardiol. 2017 Dec 19;70(24):3042-3067. (PMID: 29203195)
Contributed Indexing:
Keywords: Hemorrhage; PCC; Prothrombin complex concentrate; Reversal; Warfarin
Substance Nomenclature:
0 (Anticoagulants)
0 (Blood Coagulation Factors)
0 (Heparin Antagonists)
37224-63-8 (prothrombin complex concentrates)
5Q7ZVV76EI (Warfarin)
Entry Date(s):
Date Created: 20181117 Date Completed: 20190617 Latest Revision: 20200225
Update Code:
20240105
DOI:
10.1007/s11239-018-1768-1
PMID:
30443817
Czasopismo naukowe
Background: Four-factor PCC is the recommended standard of care for acute warfarin reversal but optimal dosing is unknown. We aim to show that a low-dose strategy is often adequate and may reduce the risk of thromboembolic events when compared to manufacturer-recommended dosing.
Methods: A weight-based dosing strategy of 15-25 units/kg was established as the institutional standard of care in May 2015. This retrospective, before-and-after cohort analysis included patients receiving 4F-PCC according to a manufacturer-recommended (n = 122) or a low-dose (n = 83) strategy. The primary efficacy outcome was a combination of INR reversal on first check and hemostatic efficacy at 24 h.
Results: Demographics, indications for warfarin, and presenting INR values were similar between the two groups. Patients in the manufacturer-recommended dose group received significantly more 4F-PCC than the low dose group (2110 units vs. 1530 units). More patients in the manufacturer-recommended dose group achieved the primary endpoint (75.4% vs. 61.4%), with more patients achieving the target INR on recheck in the manufacturer-recommended dose group (95.9% vs. 84.3%) and no difference in hemostatic efficacy between groups (79.5% vs. 74.7%). There was no difference in thromboembolic events at 72 h (4.1% vs. 1.2%) or at 30 days (8.2% vs. 4.8%). Significantly more patients in the manufacturer-recommended dose group died or were transferred to hospice care during hospitalization (21.3% vs. 9.6%).
Conclusion: Utilization of a low-dose 4F-PCC strategy resulted in fewer patients achieving target INR reversal, but no difference in hemostatic efficacy, thromboembolic events, or survival.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies